Welcome to our dedicated page for Cyclo Therapeutics news (Ticker: CYTH), a resource for investors and traders seeking the latest updates and insights on Cyclo Therapeutics stock.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is a clinical-stage biotechnology company whose news flow centers on the development of its lead investigational product, Trappsol® Cyclo™, for Niemann-Pick Disease Type C1 (NPC1) and early Alzheimer’s disease. News updates commonly highlight progress in the pivotal Phase 3 TransportNPC™ trial, data from clinical sub-studies, and regulatory and intellectual property milestones.
Investors and followers of CYTH can expect clinical trial updates, including completion of enrollment milestones, interim analyses plans, and preliminary safety and efficacy findings from the TransportNPC™ study and its open-label sub-study in very young NPC1 patients. The company frequently reports on presentations at major scientific meetings such as WORLDSymposium™ and the SSIEM Annual Symposium, where it shares poster and oral presentation data on long-term treatment, safety profiles and clinical outcomes.
Cyclo Therapeutics’ news also covers regulatory strategy developments, such as alignment with the U.S. Food and Drug Administration and European Medicines Agency on potential NDA and MAA submissions based on interim Phase 3 data, as well as the impact of Orphan Drug, Fast Track and Rare Pediatric Disease designations. In addition, the company issues updates on its Alzheimer’s disease program, including patent grants in the U.S. and Europe for methods of treating Alzheimer’s disease with Trappsol® Cyclo™ and progress in its Phase 2b trial.
Corporate and financial announcements, including quarterly and annual results, merger activity with entities such as Applied Molecular Transport and agreements with Rafael Holdings, Inc., are also part of the CYTH news stream. Readers who track CYTH news gain insight into the company’s clinical progress, regulatory path, scientific visibility and financing strategy as it advances Trappsol® Cyclo™ in rare disease and neurodegenerative indications.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that Dr. Lise Kjems, Chief Medical Officer, will present at the 2022 China Niemann Pick Medical Exchange on August 13, 2022, in Xiamen, China. The event focuses on Niemann-Pick Disease Type C (NPC) and the company's clinical development of Trappsol® Cyclo™. Dr. Kjems emphasized the need for novel therapies for NPC patients in China, highlighting ongoing research to advance treatment for this rare genetic disease.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) will participate in the 30th Annual NNPDF Family Support & Medical Conference from July 28-31, 2022, in Orlando, FL. The company aims to engage with the Niemann-Pick disease community, showcasing its Trappsol® Cyclo™ IV formulation for treating Niemann-Pick Disease Type C (NPC). Key presentations include a discussion on July 30 at 1:30 PM ET and an overview of its clinical program on July 31 at 8:45 AM ET. For more details, visit the conference website.
Cyclo Therapeutics (Nasdaq: CYTH) announced that Dr. Lise Kjems will present at the World Orphan Drug Congress USA 2022 from July 11-13, 2022, in Boston, MA. Her talk, titled From Bench to Bedside - A Review of the Trappsol Cyclo Program for the Treatment of Niemann Pick Disease Type C, is scheduled for July 13 at 3:45 PM ET. The session will cover the company’s Trappsol® Cyclo™ formulation and its clinical program targeting this rare genetic disease. The presentation will be available on the company's website following the event.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that Professor Caroline Hastings, MD, will present at the 2022 NPC Conference on June 23-24, 2022. Dr. Hastings will discuss the proprietary formulation Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C. The session includes updates from Phase I and II studies and the launch of the Phase III pivotal TransportNPC trial. The conference aims to address the urgent need for treatments for NPC patients globally. A live webcast will be available for registered attendees.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that CEO N. Scott Fine will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022 in Miami, FL, and virtually. Management will be available for one-on-one meetings with registered investors. A video webcast of the presentation will be available on demand starting May 24, 2022, at 7:00 AM ET. Cyclo Therapeutics focuses on developing medicines for rare diseases.
Cyclo Therapeutics (CYTH) reported Q1 2022 financial results, including a net loss of approximately $2.8 million. The company is advancing its lead program, Trappsol® Cyclo™, in a pivotal Phase 3 study for Niemann-Pick Disease Type C1 (NPC1) and plans to initiate a Phase 2 study for Alzheimer's Disease this year. Recent collaborations with the University of the Witwatersrand aim to expand the use of Trappsol® Cyclo™. Research and development expenses decreased by 67% to $1.1 million, while prepaid clinical expenses rose by $1.4 million. Cash reserves stand at $11.8 million.
Cyclo Therapeutics (NASDAQ: CYTH) will participate in a Virtual Investor Niemann-Pick Disease Type C (NPC) Spotlight event on May 16, 2022, at 2:00 PM ET. The company will discuss NPC, a rare genetic disorder and the development of Trappsol® Cyclo™, a treatment showing promising results in clinical studies. Key executives will join Professor Caroline Hastings, the Global Principal Investigator for the ongoing TransportNPC™ study. Cyclo Therapeutics has received Orphan Drug Designation for Trappsol® Cyclo™ in the U.S. and EU.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced its participation in the Virtual Investor Alzheimer’s Disease Spotlight event on April 5, 2022, at 1:00 PM ET. The company's management, including CEO N. Scott Fine and CMO Lise Lund Kjems, will engage in a fireside chat with key opinion leader Cynthia A. Lemere, PhD. Cyclo Therapeutics will discuss its Trappsol® Cyclo™ program for Alzheimer’s treatment, which has recently received FDA clearance for a Phase 2 study targeting early Alzheimer’s disease. The webcast will also be available for replay.
Cyclo Therapeutics (NASDAQ: CYTH) announced a research collaboration with the University of the Witwatersrand in Johannesburg to explore its proprietary Trappsol® Cyclo™ platform technology. This partnership will enhance the development of Cyclo's ongoing Phase 3 study for Niemann-Pick Disease Type C and a planned Phase 2 study for early Alzheimer’s disease. The agreement aims to advance scientific knowledge and expand Cyclo's intellectual property estate. The collaboration emphasizes the strategic importance of leveraging Wits' research capabilities for innovative therapeutic applications.
Cyclo Therapeutics, a clinical-stage biotechnology company, announced its participation in the 2022 Virtual Growth Conference hosted by Maxim Group from